Antibe Therapeutics (TSE:ATE) and Burcon NutraScience (TSE:BU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, analyst recommendations, valuation, risk and profitability.
Valuation & Earnings
This table compares Antibe Therapeutics and Burcon NutraScience's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Antibe Therapeutics | C$9.33 million | 22.68 | C$-35,814,009.00 | C($0.79) | -5.91 |
Burcon NutraScience | C$12,045.00 | 45,703.54 | C$107,101.00 | C$0.00 | 5,140.00 |
Burcon NutraScience has lower revenue, but higher earnings than Antibe Therapeutics. Antibe Therapeutics is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Antibe Therapeutics and Burcon NutraScience's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Antibe Therapeutics | N/A | N/A | N/A |
Burcon NutraScience | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of current recommendations for Antibe Therapeutics and Burcon NutraScience, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Antibe Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Burcon NutraScience | 0 | 0 | 1 | 0 | 3.00 |
Antibe Therapeutics presently has a consensus price target of C$7.75, suggesting a potential upside of 66.67%. Burcon NutraScience has a consensus price target of C$5.00, suggesting a potential downside of 2.72%. Given Antibe Therapeutics' higher probable upside, analysts plainly believe Antibe Therapeutics is more favorable than Burcon NutraScience.
Summary
Burcon NutraScience beats Antibe Therapeutics on 4 of the 7 factors compared between the two stocks.